Justin Claeys: Okay. Jullian, next question please.
Operator: Thank you, Nicole. Our next question comes from James Shin from Deutsche Bank. Please go ahead. Your line is open
James Shin: Thanks for taking our question. I have one for Jay. I just kind of want to piggyback on what Tim was alluding to. The GIP antagonism versus agonism, I’m looking at the Nature paper, it looks like 133 420-milligram dose has a slight blip in triglycerides that eventually fades, but it does seem like antagonism is behaving a little differently from the literature for agonism. Is it too early to chalk it up to antagonism versus agonism in your view? Just wanted to get your thoughts there.
Jay Bradner: The short answer is it’s too early to talk it up to antagonism versus agonism. As I said before, and I meant it, that these lipids are labile and indirect biomarker of this pharmacology. This is an early stage study that had 1 or 3 monthly doses of the medicine. And so we are not reading anything into the lipids conclusively from this trial. We are making all these measurements in the active Phase I.
Justin Claeys: Great. Then I think we have time for one more, Julianne.
Operator: Thank you, James. Our last question will come from Carter Gould from Barclays. Please go ahead. Your line is open.
Carter Gould: Good evening. Thanks for taking the questions. Maybe just one on 786. Can you walk through exactly what’s sort of driving – maybe let me take it back. Maybe first kind of if you could outline sort of how you’re setting expectations there? And any color on what’s driving the delay there? It seems like it’s taking a long time to enroll 72 patients? Thank you.
Robert Bradway: Sure. No, thank you for your question. For the broader group, AMG 786 is an oral medicine being developed for obesity. It is not an increasing that we’ve not as yet disclosed this target or pathway. This study is progressing fine. The readout of the Phase I is on track for the first half of 2024. We’ve completed initial dose escalation cohorts, and we’re just collecting and analyzing data, expecting the readout in the first half of this year.
Justin Claeys: And Julianne, we’re going to turn it back to Bob for some closing remarks.
Robert Bradway: Okay. Thank you all for joining the call. As you heard, we’re excited about the opportunities that we see for growing our business across all four of our pillars, general medicine oncology, inflammation in rare disease. Last October, we shared an in-depth look at oncology in connection with the ESMO medical meeting. And we plan to do an introductory review of rare diseases and our rare disease pillar in late February to give you more information about the medicines that we already have on the market as well as some of those that are advancing through our pipeline. So we’re encouraged by the questions that we heard on this call about those molecules, and we’re excited about them and their prospects. So we’ll host a call, which IR will share with you here over the next few days and look forward to having that opportunity.
In the meantime, again, thank you for your support, and we look forward to talking to you at the Rare Disease Day at our first quarter results call. Thank you.
Operator: This concludes our 2023 Q4 earnings call. You may now disconnect.+
